Terri Lynn Shigle

Terri Lynn Shigle

Auto-generated profile, based on publicly available information

Terri Lynn Shigle

Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
MYMichelle K. Yong
Michelle K. Yong
TSTerri Lynn Shigle
Terri Lynn Shigle
YKYae-Jean Kim
Yae-Jean Kim
PCPaul A. Carpenter
Paul A. Carpenter
RCRoy F. Chemaly
Roy F. Chemaly
GPGenovefa A. Papanicolaou
Genovefa A. Papanicolaou
The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transpl. Infect. Dis. Special Interest Group (TID-SIG) to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A new approach was employed with the goal of better serving clinical providers by publishing each standalone topic in the infectious diseases series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infectious diseases and HCT content experts developed and answered FAQs. Topics were finalized with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. The fourth topic in the series focuses on the management and treatment of cytomegalovirus (CMV) resistant and refractory infections. The diagnosis, definitions of resistant and refractory CMV, risk factors, virological genotypes and treatment algorithms are reviewed.

1 January 2020 in Therapeutic Advances in Hematology
Verified
Journal Article
Open access
PDF file
TSTerri Lynn Shigle
Terri Lynn Shigle
VHVictoria Wehr Handy
Victoria Wehr Handy
RCRoy F. Chemaly
Roy F. Chemaly
Cytomegalovirus (CMV) reactivation is one of the most common infections affecting allogeneic hematopoietic cell transplant recipients. Although available anti-CMV therapies have been evaluated for the prevention of CMV reactivation, their toxicity profile makes them unfavorable for use as primary prophylaxis; thus, they are routinely reserved for the treatment of CMV viremia or CMV end-organ disease. Pre-emptive CMV monitoring strategies have been widely accepted, and although they have been helpful in early detection, they have not affected the overall morbidity and mortality associated with CMV. Letermovir is a novel agent that was approved for primary prophylaxis in CMV-seropositive adult allogeneic hematopoietic cell transplant recipients. This review focuses on letermovir’s novel mechanism; clinical trials supporting its United States Food and Drug Administration (FDA) approval and subsequent follow-up analyses; clinical considerations, with an emphasis on pharmacology; and lessons learned from solid organ transplant recipients, as well as potential future directions.


13 October 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
UPUday R. Popat
Uday R. Popat
OPOren Pasvolsky
Oren Pasvolsky
RBRoland Bassett
Roland Bassett
RMRohtesh S. Mehta
Rohtesh S. Mehta
AOAmanda Olson
Amanda Olson
ESElizabeth J. Shpall
Elizabeth J. Shpall
Traditional conditioning regimens for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) provide suboptimal outcomes, especially for older patients and those with comorbidities. We hypothesized that a fractionated myeloablative busulfan dose delivered over an extended period would reduce nonrelapse mortality (NRM) while retaining antileukemic effects. Here, we performed a phase 2 trial for adults with hematological malignancies receiving matched related or unrelated allo-HCT. Participants received busulfan 80 mg/m2 as outpatients on days −20 and −13 before transplant. Fludarabine 40 mg/m2 was administered on days −6 to −3, followed by busulfan dosed to achieve a target area under the curve of 20 000 mol/min for the whole course. The primary end point was day-100 NRM. Seventy-eight patients were included, with a median age of 61 years (range, 39-70 years), who received transplantation for acute leukemia (24%), myelodysplastic syndrome (27%), or myeloproliferative disease/chronic myeloid leukemia (44%). HCT-specific comorbidity index (HCT-CI) was ≥3 in 34 (44%). With a median follow-up of 36.4 months (range, 2.9-51.5), the 100-day, 1-year, and 3-year NRM rates were 3.8%, 8%, and 9.3%, respectively, without a significant difference in age or HCT-CI score. The 1-year and 3-year relapse incidence was 10% and 18%, respectively. The 3-year overall survival was 80%, without a significant difference in age or HCT-CI score and was similar for patients aged >60 years and those aged <60 years as well as for those with HCT-CI ≥3 and HCT-CI <3. Overall, a myeloablative fractionated busulfan regimen has low NRM without an increase in relapse rate, resulting in promising survival, even in older patients or in patients with comorbidities. This trial was registered at www.clinicaltrials.gov as #NCT02861417.

20 August 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
HAHanan Alkhaldi
Hanan Alkhaldi
ARAlec Reinhardt
Alec Reinhardt
MBMelissa Barnett
Melissa Barnett
SKSuprateek Kundu
Suprateek Kundu
CHChitra Hosing
Chitra Hosing
YNYago Nieto
Yago Nieto
Primary mediastinal large B cell lymphoma (PMBCL) is an uncommon aggressive type of non-Hodgkin lymphoma. Rituximab-containing chemoimmunotherapy ± radiation therapy (RT) is standard first-line treatment. Relapsed or refractory (R/R) disease has long been treated with salvage chemotherapy followed by high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) in appropriate patients. We retrospectively analyzed all patients with R/R PMBCL treated with HDC/ASCT at our center between January 2000 and August 2022. Sixty patients received rituximab-BEAM (N=37) or rituximab-gemcitabine/busulfan/melphalan (R-GemBuMel) ± vorinostat (N=23), with ASCT. Forty-six patients received mediastinal RT, either as prior consolidation of frontline therapy or following ASCT. At median follow-up of 6 years (range, 0.3-21), the 5-year progression-free survival (PFS) and overall survival (OS) rates of the whole group are 58% and 77%, respectively, 51% and 65%, respectively, for R-BEAM patients, and 69% and 82%, respectively, for R-vorinostat/GemBuMel patients. Multivariable analyses showed that negative PET at ASCT [hazard ratio (HR), 0.28)] and involvement of only 1 organ (HR, 0.33) were independently associated with improved PFS. In addition, receiving R-vorinostat/GemBuMel (HR, 0.23) was an independent favorable predictor of OS. In conclusion, HDC/ASCT is effective in R/R PMBCL, with improved outcomes in patients receiving R-vorinostat/GemBuMel.

1 December 2021 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
NSNicholas A. Szewczyk
Nicholas A. Szewczyk
ANAn Ngo-Huang
An Ngo-Huang
TSTacara N. Soones
Tacara N. Soones
LALatoya M. Adekoya
Latoya M. Adekoya
RFRhodora C. Fontillas
Rhodora C. Fontillas
UPUday R. Popat
Uday R. Popat
Increasingly, patients age ≥65 years are undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT). Although age alone is a well-documented predictor of overall survival (OS) and nonrelapse mortality (NRM), growing evidence suggests that poor functional status and frailty associated with aging may have roles as well. Our goal in the present study was to identify and improve these and other aging-related maladies by developing a multimodal supportive care program for older allo-SCT recipients. We designed and implemented a multimodal supportive care program, Enhanced Recovery in Stem Cell Transplant (ER-SCT), for patients age ≥65 years undergoing allo-SCT. The ER-SCT program consists of evaluation and critical interventions by key health care providers from multiple disciplines starting before hospital admission for transplantation and extending through 100 days post-allo-SCT. We determined the feasibility of implementing this program in a large stem cell transplantation center. After 1 year of ongoing process improvements, multiple evaluations, and enrollment, we found that a dedicated weekly clinic was necessary to coordinate care and evaluate patients early. We successfully enrolled 57 of 64 eligible patients (89%) in the first year. Our data show that a multimodal supportive care program to enhance recovery for older patients undergoing allo-SCT is feasible. © 2021 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.